Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Analyst Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MLTX Stock 12 Month Forecast
Average Price Target
$77.00
▲(48.39% Upside)
| Highest Price Target$108.00 | Average Price Target$77.00 | Lowest Price Target$61.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$73
Buy
40.68%
Upside
Reiterated
08/06/25
Needham
$66
Buy
27.19%
Upside
Reiterated
08/06/25
We maintain our Buy rating and $66 PT ahead of the potentially transformative readout for SLK in HS, which we expect to drive meaningful upside in MLTX shrs and further enhance the co's M&A appeal.
LifeSci Capital
$75
Buy
44.54%
Upside
Reiterated
08/05/25
This morning, MoonLake (Nasdaq: MLTX) reported Q2 2025 earnings, finishing the quarter with $425.1M in cash, cash equivalents, and short-term marketable debt securies.
Guggenheim
$80
Buy
54.17%
Upside
Reiterated
08/05/25
TD Cowen
―
Buy
―
Reiterated
08/05/25
We recently discussed sonelokimab with a number of HS KOLs (note here). The KOLs are optimistic about sonelokimab, and expect the pivotal trial to be positive, with sonelokimab producing a competitive profile. Based on the high unmet need and the heterogenous nature of the disease, they expect it to be adopted into the treatment paradigm and see value in having multiple options even within a drug class.
RBC Capital
$67
Buy
29.12%
Upside
Reiterated
08/05/25
Wedbush
$80
Buy
54.17%
Upside
Reiterated
08/05/25
Clear Street
$108
Buy
108.13%
Upside
Reiterated
08/05/25
Redburn Atlantic
$65
Hold
25.26%
Upside
Initiated
07/28/25
Citi
$72
Buy
38.76%
Upside
Reiterated
06/02/25
H.C. Wainwright
$100
Buy
92.72%
Upside
Reiterated
05/27/25
Wolfe Research
$61
Buy
17.56%
Upside
Upgraded
05/19/25
BTIG
$81→$85
Buy
63.81%
Upside
Reiterated
04/30/25
Stifel Nicolaus
$77
Buy
48.39%
Upside
Reiterated
04/10/25
Cantor Fitzgerald
―
Buy
―
Reiterated
04/04/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$73
Buy
40.68%
Upside
Reiterated
08/06/25
Needham
$66
Buy
27.19%
Upside
Reiterated
08/06/25
We maintain our Buy rating and $66 PT ahead of the potentially transformative readout for SLK in HS, which we expect to drive meaningful upside in MLTX shrs and further enhance the co's M&A appeal.
LifeSci Capital
$75
Buy
44.54%
Upside
Reiterated
08/05/25
This morning, MoonLake (Nasdaq: MLTX) reported Q2 2025 earnings, finishing the quarter with $425.1M in cash, cash equivalents, and short-term marketable debt securies.
Guggenheim
$80
Buy
54.17%
Upside
Reiterated
08/05/25
TD Cowen
―
Buy
―
Reiterated
08/05/25
We recently discussed sonelokimab with a number of HS KOLs (note here). The KOLs are optimistic about sonelokimab, and expect the pivotal trial to be positive, with sonelokimab producing a competitive profile. Based on the high unmet need and the heterogenous nature of the disease, they expect it to be adopted into the treatment paradigm and see value in having multiple options even within a drug class.
RBC Capital
$67
Buy
29.12%
Upside
Reiterated
08/05/25
Wedbush
$80
Buy
54.17%
Upside
Reiterated
08/05/25
Clear Street
$108
Buy
108.13%
Upside
Reiterated
08/05/25
Redburn Atlantic
$65
Hold
25.26%
Upside
Initiated
07/28/25
Citi
$72
Buy
38.76%
Upside
Reiterated
06/02/25
H.C. Wainwright
$100
Buy
92.72%
Upside
Reiterated
05/27/25
Wolfe Research
$61
Buy
17.56%
Upside
Upgraded
05/19/25
BTIG
$81→$85
Buy
63.81%
Upside
Reiterated
04/30/25
Stifel Nicolaus
$77
Buy
48.39%
Upside
Reiterated
04/10/25
Cantor Fitzgerald
―
Buy
―
Reiterated
04/04/25
Best Analysts Covering MoonLake Immunotherapeutics
1 Month
xxx
Success Rate
14/25 ratings generated profit
Average Return
+11.20%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +11.20% per trade.
3 Months
xxx
Success Rate
17/25 ratings generated profit
Average Return
+33.58%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.00% of your transactions generating a profit, with an average return of +33.58% per trade.
1 Year
Success Rate
8/11 ratings generated profit
Average Return
+81.35%
reiterated a buy rating 4 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +81.35% per trade.
2 Years
xxx
Success Rate
13/14 ratings generated profit
Average Return
+15.49%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +15.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MLTX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
17
18
19
13
7
Buy
5
4
4
6
12
Hold
0
0
0
1
1
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
22
23
20
20
Each month's total comprises the sum of three months' worth of ratings.
MLTX Financial Forecast
MLTX Stock Forecast FAQ
What is MLTX’s average 12-month price target, according to analysts?
Based on analyst ratings, MoonLake Immunotherapeutics’s 12-month average price target is 77.00.
What is MLTX’s upside potential, based on the analysts’ average price target?
MoonLake Immunotherapeutics has 48.39% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLTX a Buy, Sell or Hold?
MoonLake Immunotherapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
What is MoonLake Immunotherapeutics’s price target?
The average price target for MoonLake Immunotherapeutics is 77.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $108.00 ,the lowest forecast is $61.00. The average price target represents 48.39% Increase from the current price of $51.89.
The highest analyst price target is $108.00 ,the lowest forecast is $61.00. The average price target represents 48.39% Increase from the current price of $51.89.
What do analysts say about MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of MLTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.